DOCSLIB.ORG

Laboratory: Emerging Pathogens Rollup Technical User Manual

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Laboratory: Emerging Pathogens Rollup Technical User Manual Laboratory Emerging Pathogens Initiative (EPI) Version 5.2 Roll Up Modifications Technical and User Manual September 2015 Department of Veterans Affairs (VA) Office of Information and Technology (OI&T) Product Development (PD) Revision History Date Version Description Author 9/2015 LR*5.2*442 Updates for LR*5.2*442, ICD- REDACTED 10 PTF Modifications: Updated title page and footers. Added text to Preface (p.iv), added reference to ICD-10 PTF Modifications Installation Guide (pp.21, 30), added new DBIA #6130 (p.22), updated Post Installation (p.34). 07/2014 LR*5.2*421 Updated for ICD-10 REDACTED pp. iv-ii, Remediation: Added Revision History. p. iii, Updated information in p. v Preface. p. ix-xvi Updated Orientation Updated and renumbered pp.74, 78, 111, 122, TOC. 127, 131, 135, 139, 142, 146, 149, 153, 157, 161, 165, 169, Added information on ICD-10 173, 176, 179, 183, input screens and examples. 186, 189, 193, 197, 201, 205, 214, 219 pp.16, 66, 114, 141, 144, 148, 171, 175, 178, 191, 212, 226, 234, 262, 264, 266 General changes from ICD-9 p. 362, 387 to ICD. p. 40 Updated DG1 Segment of HL7 message to utilize ~ rather pp.36, 39, 45, 50 than ^. Updated file (#69.5) file fields. Added notes that refer users to pp.229, 230 the LR*5.2*421 Release Notes for Required Patches, Installation and Post Multiple pages VistA Laboratory EPI Rollup Modifications Technical and User Manual ii September 2015 Date Version Description Author Installation instructions. Removed Personally Identifiable Information (PII). Changed AAC to Austin Information Technology Center (AITC) throughout manual 05/2008 LR*5.2*175 Initial release VA OI&T 7 VistA Laboratory EPI Rollup Modifications Technical and User Manual iii September 2015 Preface Preface The Veterans Health Information Systems and Architecture (VistA) Laboratory Emerging Pathogens Initiative (EPI) Rollup Modifications Patch LR*5.2*281 Technical and User Manual provides assistance for installing, implementing, and maintaining the EPI software application enhancements. The International Classification of Diseases, Tenth Revision (ICD-10) Remediation patch LR* 5.2*421 makes the following changes to the Emerging Pathogens Initiative (EPI) application: • The following fields and screens have been updated to refer to “ICD” rather than “ICD9”: o Laboratory Search/Extract Parameters Input screens o Enter/Edit Local Pathogens screens o Detailed Verification Report o Help text • Within the Enter/Edit Local Pathogens and Laboratory Search/Extract Parameters Input screens, users are prompted to specify a code set on which to search prior to entering an ICD code. Based on this input, the system will only allow ICD-9 entry or ICD-10 entry. • The Pathogen Inquiry option has been modified to list both ICD-9 and ICD-10 codes. • The Generate Local Report/Spreadsheet option has been modified to include both the Diagnosis Code Set Designation and the Diagnosis Code. • Health Level 7 (HL7) Reports that are sent to Austin Information Technical Center (AITC), formerly Austin Automation Center (AAC), have been modified to include ICD-10 Codes and Descriptions, which are included in the DG1 HL7 Segments. The ICD-10 PTF Modifications patch LR*5.2*442 made changes to the Emerging Pathogens Initiative (EPI) application to ensure the software would accommodate the expanded number of ICD-10 codes that may be contained in a patient record. Intended Audience The intended audience for this manual includes the following users and functionalities: • Veterans Health Administration (VHA) facility Information Resource Management (IRM) staff (will be important for installation and implementation of this package) • Laboratory Information Manager (LIM) (will be important for installation and implementation of this package) • Representative from the Microbiology section in support of the Emerging Pathogens Initiative (EPI) Rollup enhancements (i.e., director, supervisor, or technologist) (will be important for installation and implementation of this package especially with parameter and etiology determinations; may also have benefit from local functionality) VistA Laboratory EPI Rollup Modifications Technical and User Manual iv September 2015 Preface • Total Quality Improvement/Quality Improvement/Quality Assurance (TQI/QI/QA) staff or persons at the VHA facility with similar function (will be important for implementation of this package given broad-ranging impact on medical centers and cross-cutting responsibilities that extend beyond traditional service lines; may also have benefit from local functionality) • Infection Control Practitioner (likely to have benefit from local functionality) NOTE: It is highly recommend that the Office of the Director (00) at each VHA facility designate a person or persons who will be responsible for the routine implementation of this patch (both at the time of this installation and afterwards) and to take the lead in trouble-shooting issues that arise with the routine functioning of the process. This decision is left at the discretion of the director since the functions that persons perform locally may have different titles and meanings. The definitions of installation and implementation are provided below to help the Office of the Director in assigning the responsibility. The term installation refers to the process of actually integrating the software into the currently existent VistA system locally. This is usually a process that occurs over a short period of time and does not recur. By default, this process is usually accomplished by personnel in IRM. The term implementation refers to the process of executing the software after installation, adjusting parameters and maintaining the day-to-day functioning of the data cycle that the Laboratory EPI Rollup Modifications entail. There are two main functionalities that will need to be addressed by implementation (national functionality and local functionality). The national functionality will have limited local resource requirements, but will require periodic, on-going attention. Initial parameter set-up will take about 1-2 hours of time with personnel representing the LIM function, microbiology function and IRM function working in concert to set the parameters appropriately. Thereafter, a once-yearly review of the parameter set-up for all national EPI-specified pathogens is the minimum expected. Day-to-day functioning does not refer to the maintenance of the actual software patch, but, instead, refers to the EPI data cycle to assure that the national pathogen information has been appropriately sent to and received by the central data repository—by this definition, it is not necessarily the IRM function to oversee this. Because this will involve review of information sent, confirmation of information receipt, and, most importantly, troubleshooting of errors received from the processing into the central data repository, a local site function that has experience with numerous areas at the local facility from where the data are extracted (medical administrative services, social work, patient demographic information, laboratory information) and that cuts across multiple lines of authority should be considered by the Office of the Director (00) for this task. The local functionality resource requirements will be dependent upon the use at the local site. VistA Laboratory EPI Rollup Modifications Technical and User Manual v September 2015 Orientation Orientation This section of the EPI Roll Up Modifications Technical and User Manual addresses package or audience-specific notations or directions pertaining to symbols used to indicate terminal dialogues and user responses, information for accessing the EPI Technical and User Manual via the Office of Information Field Offices (OIFOs) Anonymous Software directories, VistA website, VistA Documentation Library (VDL), EPI software phased installation and implementation procedures, instructions for seeding EPI historical data, and Austin Information Technology Center (AITC) transmission schedule for seeding the EPI historical data. EPI Roll Up Modifications Technical and User Manual The EPI Roll Up Modifications Technical and User Manual contains the following sections: Introduction - conveys the major functions, purposes, and how the software accomplishes the objectives. Security Information - addresses any legal requirements pertaining to the EPI Patch LR*5.2*281, software product and identifies any security measures necessary to protect the integrity of the product and database. Pre-Installation Information - contains information that should be acknowledged prior to the installation of Patch LR*5.2*281. Installation Instructions - provides information regarding the installation process for Patch LR*5.2*281. Post Installation Instruction - provides all the necessary information required for the IRM and LIM personnel to implement the Laboratory EPI Rollup Modifications software application. EPI Rollup Modifications User Manual - provides the necessary information for implementing and maintaining the EPI criteria. Appendix A - provides instructions for editing/printing files, using input screens, linking data, and a Workload and Suffixes Codes Request Form. Appendix B - suggest helpful hints and examples regarding for EPI preferred methods, transmissions, and data validation suggestions. Appendix C - provides VistA Health Level Seven (HL7) Protocol tables used to transmit EPI Roll Up Modifications data to the Austin Information Technology Center (AITC) Appendix D - provides a copy of the IMPLEMENTATION OF LOGICAL
Load more

Recommended publications
  • Long-Term Uncontrolled Hereditary Gingival Fibromatosis: a Case Report
    Long-term Uncontrolled Hereditary Gingival Fibromatosis: A Case Report Abstract Hereditary gingival fibromatosis (HGF) is a rare condition characterized by varying degrees of gingival hyperplasia. Gingival fibromatosis usually occurs as an isolated disorder or can be associated with a variety of other syndromes. A 33-year-old male patient who had a generalized severe gingival overgrowth covering two thirds of almost all maxillary and mandibular teeth is reported. A mucoperiosteal flap was performed using interdental and crevicular incisions to remove excess gingival tissues and an internal bevel incision to reflect flaps. The patient was treated 15 years ago in the same clinical facility using the same treatment strategy. There was no recurrence one year following the most recent surgery. Keywords: Gingival hyperplasia, hereditary gingival hyperplasia, HGF, hereditary disease, therapy, mucoperiostal flap Citation: S¸engün D, Hatipog˘lu H, Hatipog˘lu MG. Long-term Uncontrolled Hereditary Gingival Fibromatosis: A Case Report. J Contemp Dent Pract 2007 January;(8)1:090-096. © Seer Publishing 1 The Journal of Contemporary Dental Practice, Volume 8, No. 1, January 1, 2007 Introduction Hereditary gingival fibromatosis (HGF), also Ankara, Turkey with a complaint of recurrent known as elephantiasis gingiva, hereditary generalized gingival overgrowth. The patient gingival hyperplasia, idiopathic fibromatosis, had presented himself for examination at the and hypertrophied gingival, is a rare condition same clinic with the same complaint 15 years (1:750000)1 which can present as an isolated ago. At that time, he was treated with full-mouth disorder or more rarely as a syndrome periodontal surgery after the diagnosis of HGF component.2,3 This condition is characterized by had been made following clinical and histological a slow and progressive enlargement of both the examination (Figures 1 A-B).
    [Show full text]
  • Hereditary Gingival Fibromatosis CASE REPORT
    Richa et al.: Management of Hereditary Gingival Fibromatosis CASE REPORT Hereditary Gingival Fibromatosis and its management: A Rare Case of Homozygous Twins Richa1, Neeraj Kumar2, Krishan Gauba3, Debojyoti Chatterjee4 1-Tutor, Unit of Pedodontics and preventive dentistry, ESIC Dental College and Hospital, Rohini, Delhi. 2-Senior Resident, Unit of Pedodontics and preventive dentistry, Oral Health Sciences Centre, Post Correspondence to: Graduate Institute of Medical Education and Research , Chandigarh, India. 3-Professor and Head, Dr. Richa, Tutor, Unit of Pedodontics and Department of Oral Health Sciences Centre, Post Graduate Institute of Medical Education and preventive dentistry, ESIC Dental College and Research, Chandigarh, India. 4-Senior Resident, Department of Histopathology, Oral Health Sciences Hospital, Rohini, Delhi Centre, Post Graduate Institute of Medical Education and Research, Chandigarh, India. Contact Us: www.ijohmr.com ABSTRACT Hereditary gingival fibromatosis (HGF) is a rare condition which manifests itself by gingival overgrowth covering teeth to variable degree i.e. either isolated or as part of a syndrome. This paper presented two cases of generalized and severe HGF in siblings without any systemic illness. HGF was confirmed based on family history, clinical and histological examination. Management of both the cases was done conservatively. Quadrant wise gingivectomy using ledge and wedge method was adopted and followed for 12 months. The surgical procedure yielded functionally and esthetically satisfying results with no recurrence. KEYWORDS: Gingival enlargement, Hereditary, homozygous, Gingivectomy AA swollen gums. The patient gave a history of swelling of upper gums that started 2 years back which gradually aaaasasasss INTRODUCTION increased in size. The child’s mother denied prenatal Hereditary Gingival Enlargement, being a rare entity, is exposure to tobacco, alcohol, and drug.
    [Show full text]
  • PHARMACEUTICAL APPENDIX to the TARIFF SCHEDULE 2 Table 1
    Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE HARMONIZED TARIFF SCHEDULE Harmonized Tariff Schedule of the United States (2020) Revision 19 Annotated for Statistical Reporting Purposes PHARMACEUTICAL APPENDIX TO THE TARIFF SCHEDULE 2 Table 1. This table enumerates products described by International Non-proprietary Names INN which shall be entered free of duty under general note 13 to the tariff schedule. The Chemical Abstracts Service CAS registry numbers also set forth in this table are included to assist in the identification of the products concerned. For purposes of the tariff schedule, any references to a product enumerated in this table includes such product by whatever name known.
    [Show full text]
  • Title 16. Crimes and Offenses Chapter 13. Controlled Substances Article 1
    TITLE 16. CRIMES AND OFFENSES CHAPTER 13. CONTROLLED SUBSTANCES ARTICLE 1. GENERAL PROVISIONS § 16-13-1. Drug related objects (a) As used in this Code section, the term: (1) "Controlled substance" shall have the same meaning as defined in Article 2 of this chapter, relating to controlled substances. For the purposes of this Code section, the term "controlled substance" shall include marijuana as defined by paragraph (16) of Code Section 16-13-21. (2) "Dangerous drug" shall have the same meaning as defined in Article 3 of this chapter, relating to dangerous drugs. (3) "Drug related object" means any machine, instrument, tool, equipment, contrivance, or device which an average person would reasonably conclude is intended to be used for one or more of the following purposes: (A) To introduce into the human body any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (B) To enhance the effect on the human body of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; (C) To conceal any quantity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state; or (D) To test the strength, effectiveness, or purity of any dangerous drug or controlled substance under circumstances in violation of the laws of this state. (4) "Knowingly" means having general knowledge that a machine, instrument, tool, item of equipment, contrivance, or device is a drug related object or having reasonable grounds to believe that any such object is or may, to an average person, appear to be a drug related object.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness Et Al
    USOO6264,917B1 (12) United States Patent (10) Patent No.: US 6,264,917 B1 Klaveness et al. (45) Date of Patent: Jul. 24, 2001 (54) TARGETED ULTRASOUND CONTRAST 5,733,572 3/1998 Unger et al.. AGENTS 5,780,010 7/1998 Lanza et al. 5,846,517 12/1998 Unger .................................. 424/9.52 (75) Inventors: Jo Klaveness; Pál Rongved; Dagfinn 5,849,727 12/1998 Porter et al. ......................... 514/156 Lovhaug, all of Oslo (NO) 5,910,300 6/1999 Tournier et al. .................... 424/9.34 FOREIGN PATENT DOCUMENTS (73) Assignee: Nycomed Imaging AS, Oslo (NO) 2 145 SOS 4/1994 (CA). (*) Notice: Subject to any disclaimer, the term of this 19 626 530 1/1998 (DE). patent is extended or adjusted under 35 O 727 225 8/1996 (EP). U.S.C. 154(b) by 0 days. WO91/15244 10/1991 (WO). WO 93/20802 10/1993 (WO). WO 94/07539 4/1994 (WO). (21) Appl. No.: 08/958,993 WO 94/28873 12/1994 (WO). WO 94/28874 12/1994 (WO). (22) Filed: Oct. 28, 1997 WO95/03356 2/1995 (WO). WO95/03357 2/1995 (WO). Related U.S. Application Data WO95/07072 3/1995 (WO). (60) Provisional application No. 60/049.264, filed on Jun. 7, WO95/15118 6/1995 (WO). 1997, provisional application No. 60/049,265, filed on Jun. WO 96/39149 12/1996 (WO). 7, 1997, and provisional application No. 60/049.268, filed WO 96/40277 12/1996 (WO). on Jun. 7, 1997. WO 96/40285 12/1996 (WO). (30) Foreign Application Priority Data WO 96/41647 12/1996 (WO).
    [Show full text]
  • 4-Aminobenzoic Acid (PABA)
    SCCP/1008/06 EUROPEAN COMMISSION HEALTH & CONSUMER PROTECTION DIRECTORATE-GENERAL Directorate C - Public Health and Risk Assessment C7 - Risk assessment SCIENTIFIC COMMITTEE ON CONSUMER PRODUCTS SCCP Opinion on 4-Aminobenzoic acid (PABA) COLIPA n° S1 Adopted by the SCCP during the 8th plenary meeting of 20 June 2006 SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ TABLE OF CONTENTS 1. BACKGROUND ………………………………………………… 3 2. TERMS OF REFERENCE ……………………………………………….... 3 3. OPINION ………………………………………………… 4 4. CONCLUSION ………………………………………………… 48 5. MINORITY OPINION ………………………………………………… 48 6. REFERENCES ………………………………………………… 48 7. ACKNOWLEDGEMENTS ………………………………………………… 56 2 SCCP/1008/06 Opinion on 4-Aminobenzoic acid (PABA) ____________________________________________________________________________________________ 1. BACKGROUND PABA or 4-Aminobenzoic acid (PABA) is listed in Annex VII part 1 no. 1 on the List of permitted UV filters that may be used in cosmetic products. The maximum authorised concentration in finished cosmetic products is 5 %. No other limitations and requirements or conditions of use and warnings are required by the SCCP. In 2001, the Commission received inquiries from Denmark expressing its concern about the use of certain UV filters in cosmetic products. In this connection an opinion on PABA was missing, as the substance has been introduced into the Annexes of the cosmetics legislation based on safety evaluations from the Member States prior to the existence of the SCCNFP. Submission I on the UV-filter 4-Aminobenzoic acid (PABA) was submitted December 2005. 2. TERMS OF REFERENCE 1. Is 4-Aminobenzoic acid (PABA) safe for continued use as a UV filter in cosmetic products under the current restriction of 5.0 % as a maximum concentration? 2. Does the SCCP consider that the use of 4-Aminobenzoic acid (PABA) is safe for the consumer in a concentration up to 5 % when used in other cosmetic products than sunscreen products? 3.
    [Show full text]
  • Diagnosis Questions and Answers
    1.0 DIAGNOSIS – 6 QUESTIONS 1. Where is the narrowest band of attached gingiva found? 1. Lingual surfaces of maxillary incisors and facial surfaces of maxillary first molars 2. Facial surfaces of mandibular second premolars and lingual of canines 3. Facial surfaces of mandibular canines and first premolars and lingual of mandibular incisors* 4. None of the above 2. All these types of tissue have keratinized epithelium EXCEPT 1. Hard palate 2. Gingival col* 3. Attached gingiva 4. Free gingiva 16. Which group of principal fibers of the periodontal ligament run perpendicular from the alveolar bone to the cementum and resist lateral forces? 1. Alveolar crest 2. Horizontal crest* 3. Oblique 4. Apical 5. Interradicular 33. The width of attached gingiva varies considerably with the greatest amount being present in the maxillary incisor region; the least amount is in the mandibular premolar region. 1. Both statements are TRUE* 39. The alveolar process forms and supports the sockets of the teeth and consists of two parts, the alveolar bone proper and the supporting alveolar bone; ostectomy is defined as removal of the alveolar bone proper. 1. Both statements are TRUE* 40. Which structure is the inner layer of cells of the junctional epithelium and attaches the gingiva to the tooth? 1. Mucogingival junction 2. Free gingival groove 3. Epithelial attachment * 4. Tonofilaments 1 49. All of the following are part of the marginal (free) gingiva EXCEPT: 1. Gingival margin 2. Free gingival groove 3. Mucogingival junction* 4. Interproximal gingiva 53. The collar-like band of stratified squamous epithelium 10-20 cells thick coronally and 2-3 cells thick apically, and .25 to 1.35 mm long is the: 1.
    [Show full text]
  • Reference Lab Users Guide
    Reference Lab Users Guide North Memorial Health Laboratory Services Philosophy Our laboratory values mutual respect, teamwork, positive attitudes, accountability, and open effective communication encouraging compassionate, remarkable care. Laboratory Accreditation The North Memorial Laboratory Services User’s Guide is a resource for facilities that use theLa Laboratoryborato Servicesry A ofc cNorthred Memorial.itatio Inn this guide you will find information you need. The User’s Guide is updated on a continuous basis. Our laboratory is CLIA certified through theThe accreditation North Memorial process Laboratory of the Services College User’s of American Guide is aPathologists resource for facilities (CAP) and that theuse theAmerican AssociationLaboratory Services of Blood of Banks North Memorial.(AABB): In this guide you will find information you need. The User’s Guide is updated on a continuous basis. Our laboratory is CLIA certified through the accreditation process of the College of American Pathologists (CAP) and the American Association of Blood Banks (AABB): College of American Pathologists AABB CAP #:18040-01 AABB #: 006331 CLIA ID #: 24D0402379 *CLIA certification obtained through CAP and AABB accreditation 1 Table of contents North Memorial Health Accreditation . 1 Lab location and phone numbers . 3 Critical Values. .8-9 Specimen Guide Order of Draw. 10 Lab Test Change (January, 2017) . .11 Laboratory Collection Procedures . 12 Microbiology Procedures . 13-37 Urinalysis Collection & Transport . 38-42 Cytology. 43-52 Histology
    [Show full text]
  • The-Anatomy-Of-The-Gum-1.Pdf
    OpenStax-CNX module: m66361 1 The Anatomy of the Gum* Marcos Gridi-Papp This work is produced by OpenStax-CNX and licensed under the Creative Commons Attribution License 4.0 Abstract The gingiva is the part of the masticatory mucosa that surrounds the teeth and extends to the alveolar mucosa. It is rmly attached to the jaw bone and it has keratinized stratied squamous epithelium. The free gingiva is separated from the tooth by the gingival groove and it it very narrow. Most of the gum is the attached gingiva. The interdental gingiva occupies the cervical embrasures in healthy gums but periodontal disease may cause it to receede. Gingival bers attach the gums to the neck of the tooth. They also provide structure to the gingiva and connect the free to the attached gingivae. Figure 1: Maxillary gingiva of a dog. More details1. This chapter is about the gums, which are also called gingivae (singular gingiva). The text will describe the structure of the gingiva and explain its role in periodontal diseases, from gingivitis to abscesses in humans and other mammals. *Version 1.1: Mar 3, 2018 8:43 pm -0600 http://creativecommons.org/licenses/by/4.0/ 1https://upload.wikimedia.org/wikipedia/commons/3/3b/Bull_Terrier_Chico_05.jpg http://cnx.org/content/m66361/1.1/ OpenStax-CNX module: m66361 2 1 Structure The gingiva is part of the masticatory mucosa2 of the mouth. This mucosa is formed by keratinized stratied squamous epithelium and it covers the dorsum of the tongue and hard palate in addition to forming the gingivae. Figure 2: The gingiva surrounds the teeth and contacts the alveolar mucosa.
    [Show full text]
  • The Use of Stems in the Selection of International Nonproprietary Names (INN) for Pharmaceutical Substances
    WHO/PSM/QSM/2006.3 The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances 2006 Programme on International Nonproprietary Names (INN) Quality Assurance and Safety: Medicines Medicines Policy and Standards The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 © World Health Organization 2006 All rights reserved. Publications of the World Health Organization can be obtained from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: [email protected]). Requests for permission to reproduce or translate WHO publications – whether for sale or for noncommercial distribution – should be addressed to WHO Press, at the above address (fax: +41 22 791 4806; e-mail: [email protected]). The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of the World Health Organization concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Prevalence of Gingival Stippling in Teenagers
    IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-ISSN: 2279-0853, p-ISSN: 2279-0861.Volume 14, Issue 9 Ver. VI (Sep. 2015), PP 94-97 www.iosrjournals.org Prevalence of Gingival Stippling in Teenagers Dler A. Khursheed1, Ranjdar M. Talabani2,Didar S. Hamagharib2, Shoxan A. Karim1, Shamal S. Zorab1,Hawzhen M. Mohammed Saeed2, Shoxan A. Hussein3 1(Department of Periodontics, School of Dentistry/ University of Sulaimani, Iraq) 2(Department of Conservative Dentistry, School of Dentistry/ University of Sulaimani, Iraq) 3(Department of Oral Diagnosis, School of Dentistry/ University of Sulaimani, Iraq) Abstract: The texture of the gingival surface may be similar to orange peel and is referred to gingival stippling. It is caused by intersection of epithelial rete ridges that causes the depression and the interspersing of connective tissue papillae between these intersections giving rise to the small bumps. Objective:The aim of the study was to determine the prevalence of gingival stippling in teenagers. Results:Among hundred and sixty-eight teenagers, 63 was male and 105 female. 86.9% of the teenagers showed gingival stippling;88.9% of the male and 85.7% of the female. The percentages of presence of gingival stippling in upper and lower jaws of male and female were 88.9%, 44.4% and 85.7%, 59.9% respectively. Conclusion:Female showed higher percentage of gingival stippling than males, and stippling was higher in upper jaw than lower jaw. Key words:Gingiva, Gingival stippling, Teenagers, I. Introduction Gingival stippling is a characteristic of the healthy attached gingiva and its diminution or loss has been considered as a sign of gingival disease.
    [Show full text]